Article
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
Targeted oncology - 1 Mar 2010
Sartore-Bianchi Andrea, Bencardino Katia, Di Nicolantonio Federica, Pozzi Federico, Funaioli Chiara, Gambi Valentina, Arena Sabrina, Martini Miriam, Lamba Simona, Cassingena Andrea, Schiavo Roberta, Bardelli Alberto, Siena Salvatore
Abstract excerpt
The introduction of KRAS testing as a diagnostic tool to select patients for epidermal growth factor receptor (EGFR)-targeted cetuximab- or panitumumab-based therapies for metastatic colorectal cancer is widely regarded as a key advance in the field of personalized cancer medicine. Oncologists are now facing emerging issues in the treatment of metastatic colorectal cancer, including: (i) the identification of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.